HOLLISTON, Mass.--(BUSINESS WIRE)--Oligo Factory, an independent manufacturer of custom oligonucleotides at scale, announced today it is opening a new oligo manufacturing facility in Holliston, MA, that will serve as the company’s new headquarters. With over 13,000 sq ft of combined bench space, offices, and labs for Oligo Factory’s next generation of synthesizers, the new facility increases Oligo Factory’s manufacturing capacity by 12x.
“Oligo Factory is uniquely positioned to help existing and new customers develop, launch, and accelerate growth of oligo-based research tools, diagnostics and therapeutics,” said Chris Boggess, CEO of Oligo Factory. “This additional capacity along with the speed and efficiency of our synthesis process will enable us to scale with our customer’s needs and market demands.”
Oligo Factory is opening its new facility after a recent growth capital investment that included Research Corporation Technologies and BroadOak Capital Partners. “The industry has a continuing need for more mid-scale production capacity. It has been great to watch the rapid progress that Chris and the team have made to position the Company to address it,” said Bill Snider, a partner at BroadOak Capital Partners.
Oligonucleotide synthesis has been an essential service to life science research and development. The use of oligonucleotides in a variety of applications, such as gene therapy, diagnostics, and basic research has led to an increase in demand for synthetic oligonucleotides. Over the last five years, commercially mature technological advancements have pushed demand for large scale synthesis beyond what the industry can currently provide. Oligo Factory has nearly two decades of experience delivering fast, cost-effective, high-quality modified and natural DNA/RNA oligonucleotide synthesis.
About Oligo Factory
Based in Holliston, MA, Oligo Factory is a leading custom oligo manufacturer at scale (mgs to kgs). Oligo Factory combines proprietary synthesis technology and exceptional customer care to deliver high-quality DNA and RNA oligonucleotides to the life sciences industry. Learn more at oligofactory.com.
About BroadOak Capital Partners
BroadOak Capital Partners is a life sciences-focused, boutique financial institution that provides direct investment and investment banking services to companies in the life sciences tools, diagnostics, and biopharma services sectors. BroadOak has made investments in more than 60 companies and advised on over 50 successful M&A transactions. For more information, visit broadoak.com.
About Research Corporation Technologies
Research Corporation Technologies is a Tucson, Arizona based technology investment and management company that provides funding and development for promising life science and biomedical companies. RCT has assets of more than $500 million to advance technology and product development through flexible, long-term investment options. To learn more about RCT, see www.rctech.com.
